XBiotech, Inc. (NASDAQ: XBIT) was founded in 2005 and is headquartered in Austin, Texas, with 73 full-time employees. It is a company that studies antibodies to rectal cancer and other symptoms. CEO John Simmard previously established CTL Immuno Therapies and AlleCure, which later became part of MannKind Biomedical (NASDAQ:MNKD) through mergers and acquisitions .
XBiotech, Inc. (XBIT):
XBiotech Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of True Human monoclonal antibodies for the treatment of various diseases.
XBiotech’s leading product Xilonix (MABp1) is a new generation of anti-cancer preparations. It has been accepted in Europe for the third phase of a randomized double-blind placebo-controlled clinical study in the treatment of advanced colorectal cancer. Xilonix targets and neutralizes interleukin-1α (IL-1α), IL-1α is a molecule that is known to promote angiogenesis, growth, tumor spread, and metabolic disorders, fatigue, anxiety-related and other advanced cancers indirectly Symptoms.
XBiotech has also developed a patented True Human monoclonal antibody discovery platform and manufacturing system.
XBiotech, Inc. (XBIT) investment:
XBiotech was listed on the Nasdaq on April 15, 2015 under the code XBIT, underwritten by WR Hambrecht. The company raised US$76 million by issuing 4 million shares (issue price of US$19 per share). Based on the issue price of $19, the market value of XBiotech is calculated to be $603 million, which means that the market value of this company at the time of IPO has exceeded the level of 92% of biotech companies in the same period.